Elsevier

The Lancet

Volume 362, Issue 9377, 5 July 2003, Pages 43-44
The Lancet

Research Letters
Effect on dyspnoea and hypoxaemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndrome

https://doi.org/10.1016/S0140-6736(03)13807-XGet rights and content

Summary

Hepatopulmonary syndrome—a complication of chronic liver disease—is characterised by hypoxaemia, which results from widespread intrapulmonary vascular dilatations. Amplified production of pulmonary nitric oxide is thought to be important in development of this disorder in patients with liver cirrhosis. Here, we report a 64-year-old man with hepatopulmonary syndrome associated with hepatitis-C-virusrelated cirrhosis. We gave the patient nebulised NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthesis, which enhanced oxygenation (arterial oxygen pressure increased from 6·98 to 9·45 kPa). After L-NAME, the distance the patient could walk in 6 min rose by 92 m. Administration of L-NAME by aerosol might offer a new approach to treatment of hepatopulmonary syndrome.

References (5)

There are more references available in the full text version of this article.

Cited by (0)

View full text